Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiotherapy, Intensity-Modulated | 1 | 2019 | 142 | 0.560 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 5 | 2016 | 234 | 0.510 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 247 | 0.510 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2016 | 1081 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 1477 | 0.440 |
Why?
|
| Patient Selection | 2 | 2020 | 696 | 0.420 |
Why?
|
| Rectal Neoplasms | 1 | 2013 | 149 | 0.380 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 806 | 0.330 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2016 | 916 | 0.330 |
Why?
|
| Lung Neoplasms | 7 | 2016 | 2526 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 801 | 0.250 |
Why?
|
| Depressive Disorder, Major | 2 | 2020 | 364 | 0.250 |
Why?
|
| Lactams, Macrocyclic | 2 | 2016 | 49 | 0.250 |
Why?
|
| Carbazoles | 2 | 2015 | 83 | 0.230 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 1313 | 0.230 |
Why?
|
| Piperidines | 2 | 2015 | 206 | 0.210 |
Why?
|
| Neoplasms | 1 | 2016 | 2671 | 0.180 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2020 | 547 | 0.170 |
Why?
|
| Pharmacogenomic Testing | 1 | 2020 | 64 | 0.160 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 180 | 0.150 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 236 | 0.140 |
Why?
|
| Pyrimidines | 3 | 2016 | 470 | 0.140 |
Why?
|
| Ipilimumab | 1 | 2017 | 33 | 0.140 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 7635 | 0.140 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 1238 | 0.140 |
Why?
|
| Aged | 7 | 2020 | 23961 | 0.130 |
Why?
|
| Eligibility Determination | 1 | 2016 | 65 | 0.130 |
Why?
|
| Age Distribution | 1 | 2016 | 392 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2016 | 375 | 0.120 |
Why?
|
| Pyrazoles | 2 | 2016 | 423 | 0.120 |
Why?
|
| Informed Consent | 1 | 2016 | 175 | 0.120 |
Why?
|
| Scleroderma, Localized | 1 | 2015 | 10 | 0.120 |
Why?
|
| Pemetrexed | 1 | 2015 | 33 | 0.120 |
Why?
|
| Acrylamides | 1 | 2015 | 57 | 0.110 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2013 | 8 | 0.110 |
Why?
|
| Spinal Neoplasms | 1 | 2013 | 32 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 2129 | 0.100 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 100 | 0.100 |
Why?
|
| Prognosis | 3 | 2016 | 4030 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2013 | 1389 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2019 | 10811 | 0.100 |
Why?
|
| Gene Rearrangement | 1 | 2013 | 150 | 0.100 |
Why?
|
| SEER Program | 1 | 2013 | 227 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 352 | 0.100 |
Why?
|
| Pyridines | 1 | 2015 | 506 | 0.090 |
Why?
|
| Male | 10 | 2020 | 67762 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2015 | 614 | 0.090 |
Why?
|
| Middle Aged | 8 | 2017 | 33479 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 889 | 0.090 |
Why?
|
| Melanoma | 1 | 2017 | 760 | 0.080 |
Why?
|
| Mutation | 3 | 2016 | 3958 | 0.080 |
Why?
|
| Prevalence | 1 | 2016 | 2734 | 0.080 |
Why?
|
| Survival Rate | 1 | 2013 | 1972 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 5742 | 0.070 |
Why?
|
| Humans | 13 | 2020 | 137585 | 0.070 |
Why?
|
| Adult | 6 | 2017 | 37929 | 0.070 |
Why?
|
| United States | 2 | 2016 | 14841 | 0.070 |
Why?
|
| Female | 9 | 2020 | 73304 | 0.070 |
Why?
|
| Lactams | 2 | 2016 | 20 | 0.060 |
Why?
|
| Aminopyridines | 2 | 2016 | 98 | 0.060 |
Why?
|
| Sulfones | 2 | 2016 | 110 | 0.060 |
Why?
|
| Drug Substitution | 1 | 2020 | 54 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 356 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 3412 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 99 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 190 | 0.030 |
Why?
|
| Dermatitis | 1 | 2015 | 20 | 0.030 |
Why?
|
| Liver Failure | 1 | 2015 | 94 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1993 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2015 | 489 | 0.030 |
Why?
|
| Radiosurgery | 1 | 2017 | 344 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 1120 | 0.030 |
Why?
|
| Binding Sites | 1 | 2015 | 1303 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2015 | 347 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 2057 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 786 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2475 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 1079 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 13209 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 15657 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 21513 | 0.010 |
Why?
|